Bispecific antibodies are an advanced class of biologics engineered to recognise and bind two distinct antigens or epitopes simultaneously. By bridging cellular interactions or co‑targeting molecular pathways, BioXCell's in vivo-ready bispecifics offer a powerful strategy for immune cell redirection, dual‑pathway blockade, payload delivery, and enhanced selectivity.
In drug discovery and translational research, bispecific antibodies are increasingly used to:
- Redirect T cells or NK cells for targeted cytotoxicity
- Engage multiple immune checkpoints
- Block redundant or compensatory signalling pathways
- Improve tumour specificity and reduce off‑target effects
- Explore novel immune‑therapeutic mechanisms in oncology, autoimmunity, and infectious disease
BioXCell’s curated bispecific antibody portfolio offers multiple formats and is designed to support the rapid development and validation of innovative therapeutic concepts, offering high‑purity, in vivo-grade reagents backed by the quality standards researchers expect.
- Anti-mouse bispecific antibodies: purpose-built, in vivo-ready bispecific reagents optimised for murine studies, closely modeled on clinical formats to support reliable mechanism‑of‑action and efficacy insights.
- Anti-human bispecific biosimilars: high-fidelity biosimilar bispecifics engineered to reflect therapeutic antibodies, enabling precise benchmarking and translational validation from discovery through development.
- Custom bispecific engineering: tailored bispecific antibody design backed by expert scientific guidance and scalable manufacturing solutions, accelerating advancement of bispecific pipelines.
BioXCell’s bispecific solutions
- Mouse-specific bispecific antibodies provide researchers the tools they need for mouse models, without having to invest in expensive humanised mice.
- Biosimilars of clinical bispecifics enable research comparisons with therapeutic formats
- Bispecifics are dual-target validated, high purity and in vivo ready, allowing researchers to run studies immediately without waiting for custom constructs
- Consistent, low endotoxin, reproducible bispecifics reduce experimental variability, helping researchers generate cleaner data faster, lowering risk and accelerating go/no-go decisions
- Researchers can use ready to ship bispecifics or choose custom services.
| Target pair | Therapeutic analogue | Species | Applications |
|---|---|---|---|
| CD3 x BCMA | Teclistamab | Human | Preclinical modeling of bispecific T-cell engager activity in multiple myeloma. |
| CD3 x GPRC5D | Talquetamab | Human | Evaluating dual-targeting strategies for resistant myeloma and T-cell redirection. |
| EGFR x MET | Amivantamab | Human | Studying receptor crosstalk, ligand competition, and resistance mechanism in epithelial tumors. |
| CD3 x CD20 | Epcortimab* | Mouse | Investigating dual B-cell targeting and T-cell engagement in syngeneic lymphoma models. |
| PD-1 x VEGF | Ivonescimab* | Mouse | Modeling immune checkpoint and angiogenic pathway interplay in mouse tumor studies. |
*Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above.
Material for download
BioXCell bispecific antibodies brochure
BioXCell bispecific antibodies product flyer
Products
Note: product availability depends on country - see product detail page.
| Details | Cat number & supplier | Size | Price |
| InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R001mg · Bio X Cell | SIM0067-R001mg Bio X Cell |
1 mg |
£410.00
1 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R001mg · Bio X Cell | SIM0069-R001mg Bio X Cell |
1 mg |
£423.00
1 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-1MG · Bio X Cell | CPB502-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) CPB501-5MG · Bio X Cell | CPB501-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R005mg · Bio X Cell | SIM0069-R005mg Bio X Cell |
5 mg |
£1635.00
5 mg
view
|
| Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) CPB501-1MG · Bio X Cell | CPB501-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control CPB500-5MG · Bio X Cell | CPB500-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control CPB500-1MG · Bio X Cell | CPB500-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R001mg · Bio X Cell | SIM0081-R001mg Bio X Cell |
1 mg |
£423.00
1 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R005mg · Bio X Cell | SIM0081-R005mg Bio X Cell |
5 mg |
£1635.00
5 mg
view
|
| InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R005mg · Bio X Cell | SIM0067-R005mg Bio X Cell |
5 mg |
£1587.00
5 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-5MG · Bio X Cell | CPB502-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R025mg · Bio X Cell | SIM0069-R025mg Bio X Cell |
25 mg |
£5707.00
25 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R025mg · Bio X Cell | SIM0081-R025mg Bio X Cell |
25 mg |
£5707.00
25 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-25MG · Bio X Cell | CPB502-25MG Bio X Cell |
25 mg |
£42591.00
25 mg
view
|
